Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10630944 | 0.88 | ALDH1A1 (0.57) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL27371604 | 0.87 | ITGB3 (0.54) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL12516004 | 0.85 | SMN1; SMN2 (0.62) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL11118792 | 0.84 | HDAC6 (0.54) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL10123874 | 0.83 | TERT (0.55) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL3650167 | 0.83 | HPGD (0.54) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL8298056 | 0.83 | KDM4E (0.53) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPSR1 | |
| Hydrochloric Acid SCHEMBL10771309 | 0.83 | HDAC6 (0.52) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL7900184 | 0.83 | PRSS1 (0.53) | KDM4EALDH1A1SMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL279941 | 0.83 | RAB9A (0.62) | KDM4EALDH1A1SMN1; SMN2HSD17B10HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| CN-101076519-A | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL IND LTD (JP) | 2007-11-21 | — | — | CN | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-6858641-B2 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-22 | — | — | US | disclosed |
| CN-1509270-A | Indolinones substituted in the 6-position, process for their preparation and their use as kinase inhibitors | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-06-30 | — | — | CN | disclosed |
| EP-1379501-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20030092756-A1 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-05-15 | — | — | US | disclosed |
| WO-2002081445-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092756-A1 | Substituted indolinones | CDK1, CDK2, CDKL1 | KDM4E 695/4885ALDH1A1 1526/4885SMN1; SMN2 4355/4885 |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | KDM4E 4435/4885ALDH1A1 2047/4885SMN1; SMN2 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.